Reviewing Matinas BioPharma Holdings (MTNB) and Senestech (SNES)
Matinas BioPharma Holdings (NASDAQ: MTNB) and Senestech (NASDAQ:SNES) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.
This is a breakdown of current ratings and price targets for Matinas BioPharma Holdings and Senestech, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Matinas BioPharma Holdings||0||0||3||0||3.00|
Matinas BioPharma Holdings presently has a consensus price target of $7.67, suggesting a potential upside of 523.31%. Senestech has a consensus price target of $14.50, suggesting a potential upside of 806.25%. Given Senestech’s higher possible upside, analysts clearly believe Senestech is more favorable than Matinas BioPharma Holdings.
Institutional and Insider Ownership
15.3% of Senestech shares are owned by institutional investors. 27.4% of Senestech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This table compares Matinas BioPharma Holdings and Senestech’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Matinas BioPharma Holdings||-8,834.65%||-143.22%||-79.91%|
Earnings and Valuation
This table compares Matinas BioPharma Holdings and Senestech’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Matinas BioPharma Holdings||$59,875.00||1,889.36||-$12.81 million||N/A||N/A|
Senestech has higher revenue and earnings than Matinas BioPharma Holdings.
Senestech beats Matinas BioPharma Holdings on 6 of the 10 factors compared between the two stocks.
About Matinas BioPharma Holdings
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections. Its cochleate delivery technology platform is designed for the targeted delivery of pharmaceuticals directly to the site of infection or inflammation. Its MAT 2203 is an oral formulation of a spectrum anti-fungal drug called amphotericin B, which uses its cochleate delivery technology. Its MAT2501 is an orally administered, encochleated formulation of the spectrum aminoglycoside antibiotic amikacin, which may be used to treat different types of multidrug-resistant bacteria, including non-tubercular mycobacterial infections (NTM), as well as various multidrug-resistant gram negative and intracellular bacterial infections.
SenesTech, Inc. is a United States-based biotechnology platform and research company. The Company is engaged in developing a technology for managing animal populations by fertility control. It offers ContraPest, a fertility control product candidate. ContraPest’s technology and approach targets the reproductive capabilities of both sexes. Using bait stations, ContraPest is dispensed in a palatable liquid formulation that promotes sustained consumption by rodent communities. Its formulation causes both female and male rats to become infertile once they have consumed the dose. The active ingredient in females accelerates the rate at which ovarian follicles (egg structures) are depleted. Once these cells are gone, the animal cannot reproduce. In males, there is a marked reduction in the ability to fertilize eggs and, often complete sterility. ContraPest is designed, formulated and dispensed for handlers and non-target species, such as wildlife and pets in a biodegradable product.
Receive News & Ratings for Matinas BioPharma Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.